新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 默克 » 默克与MorphoSys达成免疫肿瘤学战略合作

默克与MorphoSys达成免疫肿瘤学战略合作

来源:生物谷 2014-06-13 10:44

2014年6月13日讯 /生物谷BIOON/ --默克(Merck)和MorphoSys公司6月12日联合宣布,双方已签署了一项免疫肿瘤学合作协议,发现和开发针对未公开免疫检查点的治疗性抗体。该项协议的财务条款尚未披露。

根据协议条款,默克旗下雪兰诺(Merck Serono)将与MorphoSys联手开发免疫疗法,调节免疫系统对抗肿瘤的自然能力。MorphoSys是全人源化抗体技术的领导者,该公司将应用其专有的Ylanthia抗体噬菌体文库和技术平台,鉴定靶向特定靶标的抗体。默克雪兰诺将负责所鉴定抗体的I期临床。

通过此次合作,默克雪兰诺将致力于加强现有的癌症免疫疗法组合,作为单药疗法或与其他治疗性调节剂进行联合用药。该公司的免疫肿瘤学管线资产,横跨I期到III期针对多种不同癌症类型,包括tecemotide及2种免疫细胞因子NHS-IL2和NHS-IL12、抗PD-L1单抗等。除此之外,默克雪兰诺已在3个创新集群(治疗性癌症疫苗,癌症干细胞,肿瘤免疫耐受)建立了一个强大的临床前管线。(生物谷Bioon.com)

英文原文:MorphoSys and Merck Serono Enter Strategic Immuno-Oncology Collaboration

June 12, 2014 / 7:30 am, CET

Co-development and license agreement that complements and further expands Merck Serono's immuno-oncology portfolio
MorphoSys' Ylanthia next-generation antibody technology to be leveraged for the rapid identification of inhibitors against immune checkpoints
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and Merck today announced that they have signed an agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints.

Under the terms of the agreement, MorphoSys and Merck Serono, the biopharmaceutical division of Merck, will join forces to develop therapies that modulate the immune system's natural ability to fight tumors. MorphoSys, a leader in fully human antibody technologies, will apply its proprietary Ylanthia? antibody phage library and technology platform to identify antibodies against the targets of interest. Merck Serono with its strong portfolio and capabilities in the field of immuno-oncology and clinical development will be fully responsible for execution of development from Phase 1 onwards.

"The establishment of partnerships with companies with innovative technology platforms is an integral part of Merck Serono's strategy to further expand upon our already diverse immuno-oncology portfolio," said Dr. Helen Sabzevari, Senior VP of Immuno-Oncology at Merck Serono. "Combining Merck Serono's extensive expertise in immuno-oncology with MorphoSys's next-generation antibody technology provides us with an exciting opportunity to rapidly generate novel therapies with a clear potential to benefit cancer patients."

"Therapeutic agents in the immuno-oncology field are set to transform cancer therapy, and we are delighted to work with Merck Serono in this area", commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys. "We believe that our Ylanthia technology has the potential to provide truly differentiated antibodies against the targets that will be the subject of the collaboration. Merck Serono's expertise in immuno-oncology, together with their strength in developing and commercializing therapeutic antibodies make them an ideal partner for MorphoSys."

With this partnership, Merck Serono, is committed to strengthen its existing portfolio of cancer immunotherapies that work as monotherapies or in combination with other therapeutic modalities. The company's immuno-oncology pipeline assets currently investigated in clinical trials span from Phase 1 to Phase 3 for the treatment of different cancer types, including tecemotide, a MUC1 antigen-specific cancer immunotherapy, the two immunocytokines NHS-IL2 (MSB0010445) and NHS-IL12 (MSB0010360), and the monoclonal antibody anti-PD-L1 (MSB0010718C). Beyond this, Merck Serono has built a robust pre-clinical pipeline in the three innovation clusters therapeutic cancer vaccines, cancer stem cells, and tumor immunotolerance.

Under the terms of the co-development and license agreement, MorphoSys will co-fund research & development costs with the option to opt-out at predefined stages. MorphoSys will be eligible to receive development and commercial milestone payments, and in addition, tiered royalties on product sales that will reflect the extent of MorphoSys co-funding. Merck Serono will have sole responsibility for commercializing of any resulting products. Further financial details are not being disclosed.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库